Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13216166 | 0.84 | KDM4E (0.65) | ALDH1A1KDM4EPKMHPGDHCRTR1 | |
| SCHEMBL16433946 | 0.80 | SMN1; SMN2 (0.56) | ALDH1A1KDM4EPKMHPGDSMN1; SMN2 | |
| SCHEMBL270496 | 0.77 | ALPL (0.47) | ALDH1A1HCRTR1HCRTR2MAPK1KMT2A | |
| SCHEMBL12597766 | 0.76 | SMN1; SMN2 (0.51) | ALDH1A1KDM4EPKMHPGDSMN1; SMN2 | |
| SCHEMBL17621930 | 0.76 | SMN1; SMN2 (0.51) | ALDH1A1KDM4EPKMHPGDHCRTR1 | |
| SCHEMBL19222069 | 0.76 | SMN1; SMN2 (0.51) | ALDH1A1KDM4EPKMHPGDSMN1; SMN2 | |
| SCHEMBL268643 | 0.75 | KDM4E (0.49) | ALDH1A1KDM4EHPGDHCRTR1HCRTR2 | |
| SCHEMBL270041 | 0.75 | HCRTR1 (0.44) | HCRTR1HCRTR2DHODH | |
| SCHEMBL923718 | 0.75 | KDM4E (0.53) | KDM4EPKMHCRTR1HCRTR2NPC1 | |
| SCHEMBL984476 | 0.74 | KMO (0.49) | HCRTR1HCRTR2SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160081997-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-24 | — | — | US | disclosed |
| US-20160081997-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-24 | — | — | US | disclosed |
| US-9227935-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICAL N.V. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-9227935-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICAL N.V. (BE) | 2016-01-05 | — | — | US | disclosed |
| US-20150087629-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | disclosed |
| US-20150087629-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-03-26 | — | — | US | disclosed |
| US-8946228-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-02-03 | — | — | US | disclosed |
| US-8946228-B2 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2015-02-03 | — | — | US | disclosed |
| EP-2155198-B1 | Piperidine/piperazine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-13 | — | — | EP | disclosed |
| US-20100210618-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| US-20100210618-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-08-19 | — | — | US | disclosed |
| WO-2008148849-A2 | PIPERIDINE/PIPERAZINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210618-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, NAT1 | ALDH1A1 150/4885KDM4E 3597/4885PKM 4026/4885 |
| US-20150087629-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, NAT1, SOAT1 | ALDH1A1 189/4885KDM4E 3538/4885PKM 4030/4885 |
| US-20160081997-A1 | PIPERIDINE/PIPERAZINE DERIVATIVES | DGAT1, DGAT2, SOAT1 | ALDH1A1 231/4885KDM4E 3529/4885PKM 4049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.